Review
Open access
Aug 2026
HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial
HLX07 monotherapy has demonstrated promising efficacy and a favorable safety profile in treating aCSCC, warranting further investigation in large-scale clinical studies.
Chang-Xing Li, Kang Zeng, Dong-Yuan Zhu et al.
· Therapeutic Advances in Medi... · 0 citations